Female Infertility | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2018

MARKET OUTLOOK

Female infertility is typically defined as the inability to achieve pregnancy after one year of attempting conception. A wide range of factors may cause female infertility, such as age, obesity, type 2 diabetes, and endometriosis. As such, there are numerous avenues to help these patients successfully conceive, including pharmacologic agents such as clomiphene citrate and follicle-stimulating hormone (e.g., Merck KGaA’s Gonal F), as well as assisted reproductive technologies including in vitro fertilization. Thus, patient-specific considerations are often needed to determine the optimal plan for initiation of treatment. Pipeline agents (e.g., ObsEva’s nolasiban) are seeking to capitalize on unmet need for improving pregnancy rates, particularly for patients undergoing assisted reproductive technology-based procedures.

QUESTIONS ANSWERED

• How large is the prevalent population of females patients suffering from infertility?
• What are the most common causes of female infertility? Is this expected to change in the next 10 years?
• What are current treatment options for female infertility? How do reproductive endocrinologists approach different underlying causes of female infertility?
• What unmet needs remain for the treatment of different drivers of infertility?
• What are the most promising pipeline agents? How do experts believe these will fit into future treatment paradigms?

PRODUCT DESCRIPTION

Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

RELEASE DATE

July 2018

GEOGRAPHIES

United States and EU5

PRIMARY RESEARCH

• Six country-specific interviews with thought-leading reproductive endocrinologists
• Supported by survey data collected for this study

EPIDEMIOLOGY

Total, diagnosed, and drug-treated prevalent cases of female infertility by country, total prevalent cases by etiology, number of procedures due to female infertility

FORECAST

Drug-level sales and patient share of key female infertility therapies in 2027

EMERGING THERAPIES

Phase III/PR: 1 drugs. Phase II: 2 drugs. Coverage of select preclinical and Phase I products.